Literature DB >> 1574800

Rapid HLA-DRB1 genotyping by nested PCR amplification.

G Bein1, R Gläser, H Kirchner.   

Abstract

State of the art genotyping of HLA class II alleles with group-specific DNA amplification by the polymerase chain reaction (PCR) (1) and subsequent probing with sequence-specific oligonucleotides (2-4) is not suitable for typing cadaveric organ donors since the typing procedure takes far more than one working day. We designed specific oligonucleotide primer sets for nested PCR amplification which allowed typing for all serological HLA-DR specificities (DR1-DRw18) solely by the detection of amplified DNA in the reaction mixtures after agarose gel electrophoresis. Exon 2 of the DRB genes and a DRw52-group-specific part of DRB1 exon 2 was amplified directly from cell lysates without prior DNA extraction. The amplified DNA was subjected to a second round of amplification, which employed a set of 18 nested allele- or group-specific primer pairs. All alleles which have at least a single mismatched base at the terminal 3'-nucleotide of one primer were completely refractory to amplification. This assay is easy to perform and takes less than one working day to complete. Thus, this method may prove to be suitable for DNA typing of organ donors for prospective HLA-DR matching in renal transplantation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1574800     DOI: 10.1111/j.1399-0039.1992.tb01909.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  17 in total

1.  Analysis of Epstein-Barr virus (EBV) receptor CD21 on peripheral B lymphocytes of long-term EBV- adults.

Authors:  W J Jabs; M Paulsen; H J Wagner; H Kirchner; H Klüter
Journal:  Clin Exp Immunol       Date:  1999-06       Impact factor: 4.330

2.  Characterisation of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment.

Authors:  M Leuschner; C F Dietrich; T You; C Seidl; J Raedle; G Herrmann; H Ackermann; U Leuschner
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

3.  Variability in the interpretation of microsatellite patterns with different electrophoretic conditions.

Authors:  A C Santos; Y Yamaoka; D Y Graham; A R Sepulveda
Journal:  Mol Pathol       Date:  1999-10

4.  Monitoring of a new approach of immunotherapy with allogenic (111)In-labelled NK cells in patients with renal cell carcinoma.

Authors:  Birgit Meller; Christoph Frohn; Jörg-Matthias Brand; Isabel Lauer; Lutz F Schelper; Katharina von Hof; Holger Kirchner; Eckart Richter; Manfred Baehre
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12-19       Impact factor: 9.236

5.  The relationship of lmp2 and DR3 genes with susceptibility to type I diabetes mellitus in south China Han population.

Authors:  He-Li Ding; Hua Cheng; Zu-Zhi Fu; Qing-Li Deng; Li YanLAST_NAME> Tang Yan; Tang Yan
Journal:  World J Gastroenterol       Date:  2000-02       Impact factor: 5.742

6.  HLA-B*27 typing by sequence specific amplification without DNA extraction.

Authors:  D C Sayer; H S Cassell; F T Christiansen
Journal:  Mol Pathol       Date:  1999-10

7.  Nucleotide sequence of a novel HLA-DRB1 allele, DRB1*0806.

Authors:  D Loeffler; A Woelpl; T H Eiermann
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

8.  Autoimmune responses to the beta cell autoantigen, insulin, and the INS VNTR-IDDM2 locus.

Authors:  E Sarugeri; N Dozio; C Belloni; F Meschi; M R Pastore; E Bonifacio
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

9.  HLA-DR typing for kidney transplants: advantage of polymerase chain reaction with sequence specific primers in a routine hospital laboratory.

Authors:  C Lynas; N J Hurlock; J A Copplestone; A G Prentice; R J McGonigle
Journal:  J Clin Pathol       Date:  1994-07       Impact factor: 3.411

10.  Evaluation of a novel mononuclear cell isolation procedure for serological HLA typing.

Authors:  P Schlenke; H Klüter; M Müller-Steinhardt; H J Hammers; K Borchert; G Bein
Journal:  Clin Diagn Lab Immunol       Date:  1998-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.